These Analysts Boost Their Forecasts On Sage Therapeutics Following Q4 Results

Sage Therapeutics, Inc. SAGE reported better-than-expected fourth-quarter revenue results on Wednesday.

Sage Therapeutics posted a quarterly loss of 55 cents per share. The company’s quarterly sales came in at $77.97 million compared to market estimates of $60.98 million, according to data from Benzinga Pro.

"2023 was a pivotal year for Sage, with key accomplishments achieved across our pipeline, culminating with the recent encouraging launch of ZURZUVAE, the first-and-only once daily oral treatment for adults with postpartum depression. We are incredibly pleased with the early progress on the launch. I am proud of our team’s relentless work toward our goal of ZURZUVAE becoming the first line therapy for women with PPD and believe strongly in the potential for ZURZUVAE to make an impact in treating this devastating disease," said Barry Greene, Chief Executive Officer at Sage Therapeutics.

Sage Therapeutics shares slipped 0.2% to trade at $25.71 on Thursday.

These analysts made changes to their price targets on Sage Therapeutics after the company reported quarterly results.

• RBC Capital boosted the price target on Sage Therapeutics from $21 to $26. RBC Capital analyst Brian Abrahams maintained a Sector Perform rating.
• HC Wainwright & Co. increased the price target on Sage Therapeutics from $25 to $28. HC Wainwright & Co. analyst Douglas Tsao maintained a Neutral rating.

Also Check This Out: Top 4 Health Care Stocks You May Want To Dump In February